10 results about "Inhalant Solution" patented technology

The present application relates to a kind of biomimetic lung surfactant carrier, which is prepared from total fat and simulation peptide, in the total fat, the mass ratio of dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylglycerol, dipalmitoyl phosphatidyl ethanolamine-polyethylene glycol 2000, cholesterol is 8-12:1:1:1;The lung surfactant simulation peptide is the simulation peptide of SP-B protein and / or the simulation peptide of SP-C protein.The biomimetic lung surfactant carrier has the advantages of high loading rate and high stability.The present application also relates to inhalation dosage form of drug for treating pulmonary arterial hypertension loaded by the biomimetic lung surfactant carrier, which makes the loaded drug obtain more uniform intra-pulmonary distribution, the inhalation drug is more close to natural lung surfactant in composition and physiological function, can delay the degradation of product, improve the utilization rate of drug, achieve good pulmonary arterial hypertension treatment effect.

The invention provides a polypeptide coupling medicine and application thereof. The polypeptide coupling medicine comprises antiviral polypeptide, connecting polypeptide, amino acid and ambroxol which are connected in sequence. The polypeptide coupling drug provided by the invention is obtained by coupling a coronavirus membrane fusion inhibitor and ambroxol, and is formed by coupling polypeptide serving as a targeting carrier and a load drug through a connexon via a covalent bond. Through polypeptide coupled drug activity evaluation and pharmacokinetic research, evaluation of activity changes of polypeptide and ambroxol and research on drug exposure and half-life periods of inhalants and injections, the polypeptide coupled drug retains antiviral activity of polypeptide and phlegm eliminating / respiratory tract regulating functions of ambroxol, the drug exposure is increased, and the half-life period is prolonged.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The invention belongs to the field of pharmaceutical preparations, and discloses a long-acting dry powder microsphere inhalant as well as a preparation method and application thereof. The inhalant is a long-acting dry powder microsphere inhalant prepared by taking a mixture of multi-cystic vesicles prepared from phospholipid and a dry powder auxiliary material as a drug carrier and entrapping active ingredients for treating lung diseases through a spray drying technology. Compared with a dry powder microsphere inhalant prepared from traditional monocystic lipidosome, the long-acting dry powder microsphere inhalant has a longer-time slow-release effect. According to the preparation, a unique process of firstly preparing multi-capsule vesicles and then performing spray drying is adopted, the obtained microspheres have an aerodynamic particle size of 1-5 microns, can be effectively deposited in the lung and show a remarkable long-acting slow-release characteristic, and the cumulative release rate reaches about 64% after 48-hour in-vitro release. Compared with a traditional monocystic liposome inhalant, the drug action time is effectively prolonged, the administration frequency is reduced, and the patient compliance is improved. The invention provides a new thought for the research of a pulmonary drug delivery system, and has a wide clinical application prospect.

The invention discloses an exercise physiological monitoring and intelligent dosing integrated protector device which comprises a chest fixing band and a shoulder fixing band. The shoulder fixing band is movably installed on one side of the chest fixing band, a containing disc is fixedly arranged in the middle of the chest fixing band, and sensors used for monitoring breathing, heart rate and blood oxygen of a user are arranged at the rear end of the containing disc; by means of the multiple sensors, the physiological indexes of a user during exercise can be monitored, the conditions of breathing, heart rate, blood oxygen and the like of the user are monitored, and different physiological indexes are monitored, so that whether the user is about to have the illness condition or not is judged, and the early warning function can be achieved; meanwhile, the nasal cavity spray head used for aerosol inhalation is wound on the containing disc, and the inhalant can be supplied to the asthma patient for inhalation through the nasal cavity spray head.

The invention provides naringin dry powder inhalation as well as a preparation method and application thereof, belongs to the technical field of pharmaceutical preparations, and particularly provides the naringin dry powder inhalation which comprises the following components in parts by mass: 1-30 parts of micronized naringin and 40-100 parts of a diluent, and the particle size distribution D90 of the micronized naringin is 1-30 [mu] m. The naringin dry powder inhalation provided by the invention is an inhalation administration preparation, has the advantages of high drug absorption rate and quick response, and the naringin dry powder inhalation provided by the invention has extremely low bitter taste and good patient compliance, and can be used for preparing an anti-inflammatory drug inhalant and / or a lung disease treatment drug.

This invention discloses a method for preparing a bumetanide nasal administration formulation and its application in the treatment of epilepsy, belonging to the field of pharmaceutical technology. The nasal administration formulation is a bumetanide nasal spray and / or a bumetanide dry powder inhaler. The drug is used for immediate administration intervention within 30 minutes after an epileptic seizure in non-medical settings, including at home, outdoors, or during transport. In this invention, the bumetanide nasal spray or dry powder inhaler does not require intravenous puncture or operation by professional medical personnel. Patients or their families can administer the drug directly through the nasal cavity within 30 minutes after an epileptic seizure at home, outdoors, or during transport, breaking through the dependence of traditional intravenous injection on medical settings and equipment, and buying valuable time for neuronal resuscitation.

A method for estimating an inhale dose when a drug is delivered to a person using an inhaler is disclosed. A predicted inhale dose (PID) of the drug is estimated based on at least one first-type parameter and at least one second-type parameter. The first-type parameter is related to a breath pattern of the person, and the second-type parameter is related to the inhaler.

The invention relates to application of an RIPK2 inhibitor GSK2983559 in preparation of drugs for preventing, treating and / or relieving pulmonary fibrosis, a novel strategy with great potential is provided for development of novel anti-pulmonary fibrosis drugs, GSK2983559 is clear in chemical structure and good in stability, can be easily prepared into various dosage forms such as injections and aerosol inhalers, can be applied to whole-body administration and local treatment, and can be applied to preparation of drugs for preventing, treating and / or relieving pulmonary fibrosis. The method is suitable for pulmonary fibrosis patients at different stages, and has good clinical transformation prospects and industrialization feasibility.